01 /What it is
Semaglutide is a synthetic GLP-1 receptor agonist with structural modifications that extend its half life to approximately one week in research models. It is a prescription medicine in regulated markets and one of the most studied GLP-1 analogs in current research.
02 /How it works
In research models, Semaglutide is studied as a long acting GLP-1 receptor agonist. Its mechanism is investigated in incretin pathway research, satiety pathway research, and gastric emptying research.
03 /What researchers explore it for
Researchers have explored Semaglutide in GLP-1 receptor research, in incretin pathway research, and in body composition research alongside dual incretin agonists.
04 /Safety and interactions
Research interactions of note include overlapping pathway engagement with other GLP-1 receptor agonists, dual incretin agonists, and triple agonists. Semaglutide is also a prescription medicine in regulated markets. Semaglutide is for laboratory research use only and is not for human consumption. Not medical advice. Not intended to diagnose, treat, cure, or prevent any disease.
05 /Research notes
Compound family: long acting GLP-1 receptor agonists. Frequently compared with Liraglutide, Tirzepatide, and Retatrutide. The Apothify library lists Semaglutide for encyclopedia coverage only.
Related peptides
Liraglutide · Tirzepatide · Retatrutide